Related Experiment Videos
Benoîte Mery1, Philippe Toussaint1, Pierre-Etienne Heudel1
1Centre Léon-Bérard, département de cancérologie médicale, 28, rue Laennec, 69008 Lyon, France.
Bulletin Du Cancer
|December 31, 2021
Summary
Novel therapies are emerging for HER2-positive breast cancer, offering new hope against treatment resistance. This review explores advanced strategies and future directions for managing this common cancer subtype.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- HER2-amplification in breast cancer affects 20% of cases.
- Anti-HER2 therapies, particularly monoclonal antibodies, have significantly improved patient outcomes since 2000.
- Emerging resistance to current HER2-targeted treatments necessitates novel therapeutic strategies.
Purpose of the Study:
- To provide an updated overview of novel therapeutic strategies for HER2-positive breast cancer.
- To discuss future perspectives in both adjuvant and metastatic settings.
- To address the challenge of therapeutic resistance in HER2-positive breast cancer management.
Main Methods:
- Literature review of recent advancements in HER2-positive breast cancer treatment.
- Analysis of emerging therapeutic targets within the HER receptor family.
- Synthesis of data on novel treatment strategies and their clinical implications.
Main Results:
- Significant progress has been made in developing new agents targeting the HER receptor family.
- Several novel therapeutic strategies show promise in overcoming resistance mechanisms.
- Future research directions include combination therapies and personalized treatment approaches.
Conclusions:
- The landscape of HER2-positive breast cancer treatment is rapidly evolving with new therapeutic options.
- Addressing treatment resistance is crucial for further improving patient survival and outcomes.
- Continued research and clinical trials are essential to validate and implement novel strategies.